The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort

Rheumatology (Oxford). 2024 Feb 1;63(2):e39-e42. doi: 10.1093/rheumatology/kead395.

Authors

Alessandro Tomelleri^{1

2}, Giovanni Benanti^{1

2}, Adriana Cariddi¹, Stefania Laura Calvisi¹, Elena Baldissera¹, Nicola Boffini¹, Marco Matucci-Cerinic^{1

3}, Lorenzo Dagna^{1

2}

Affiliations

¹ Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy.
² Vita-Salute San Raffaele University, Milan, Italy.
³ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

No abstract available

MeSH terms

Arthritis, Rheumatoid*
Humans
Janus Kinase Inhibitors* / therapeutic use
Janus Kinases
Prospective Studies

Substances

Janus Kinase Inhibitors
Janus Kinases

Grants and funding

AstraZeneca